ABSTRACT

Epilepsy is a common chronic disorder of the brain and can be seen at all ages with a higher prevalence in developing countries. Adjunctive therapy with antiepileptic drugs (AEDs) is the gold standard in treatment of epilepsy. Lacosamide (LCM) is a novel AED which is approved for adjunctive therapy for the treatment of partial-onset seizures. Recently 3 Phase II/III placebo controlled clinical trials with similar designs were conducted to investigate the efficacy and safety of lacosamide (LCM) administered as adjunctive therapy with other AEDs. Data collected from those studies were pooled, re-analyzed and presented in this review article. Results revealed that LCM is well tolerated and effective in seizure reduction as adjunctive therapy in patients with uncontrolled partial-onset seizures.